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Genome-Wide Significant Schizophrenia
Risk Variation on Chromosome 10q24 Is
Associated With Altered cis-Regulation of
BORCS7, AS3MT, and NT5C2 in the
Human Brain.
Am J Med Genet Part B 9999:1–9.Chromosome 10q24.32-q24.33 is one of the most robustly
supported risk loci to emerge from genome-wide association
studies (GWAS) of schizophrenia. However, extensive linkage
disequilibrium makes it difficult to distinguish the actual
susceptibility gene(s) at the locus, limiting its value for
improving biological understanding of the condition. In the
absence of coding changes that can account for the associa-
tion, risk is likely conferred by altered regulation of one or
more genes in the region. We, therefore, used highly sensitive
measures of allele-specific expression to assess cis-regulatory
effects associated with the two best-supported schizophrenia
risk variants (SNP rs11191419 and indel ch10_104957618_I/
rs202213518) on the primary positional candidates BORCS7,
AS3MT, CNNM2, and NT5C2 in the human brain. Heterozy-
gosity at rs11191419 was associated with increased allelic
expression of BORCS7 and AS3MT in the fetal and adult
brain, and with reduced allelic expression of NT5C2 in the
adult brain. Heterozygosity at ch10_104957618_I was associ-
ated with reduced allelic expression of NT5C2 in both the
fetal and adult brain. Comparisons between cDNA ratios in
heterozygotes and homozygotes for the risk alleles indicated
that cis-effects on NT5C2 expression in the adult dorsolateral
prefrontal cortex could be largely accounted for by genotype
at these two risk variants. While not excluding effects on
other genes in the region, this study implicates altered neural
expression of BORCS7, AS3MT, and NT5C2 in susceptibility
to schizophrenia arising from genetic variation at the chro-
mosome 10q24 locus.
 2016 The Authors. American Journal of Medical Genetics Part B: Neuro-
psychiatric Genetics Published by Wiley Periodicals, Inc.
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Chromosome 10q24.32-q24.33 is one of the best-supported
genetic risk loci to arise from large-scale genome-wide association
studies (GWAS) of schizophrenia [Schizophrenia Psychiatricropsychiatric Genetics Published by Wiley Periodicals, Inc. 1
2 AMERICAN JOURNAL OF MEDICAL GENETICS PART BGenome-Wide Association Study Consortium, 2011; Ripke et al.,
2013; Schizophrenia Working Group of the Psychiatric Genomics
Consortium, 2014]. Variation at this locus also exhibits genome-
wide significant association with the five disorders included in
the Psychiatric Genomics Consortium combined [Cross-Disorder
Group of the Psychiatric Genomics Consortium, 2013], suggesting
that it increases susceptibility to psychiatric disorders in general.
However, like many other loci identified by schizophrenia
GWAS, extensive linkage disequilibrium in the region results
in association signals spanning multiple genes (Fig. 1), making it
difficult to predict the actual susceptibility gene(s) at the locus.
As with the majority of genome-wide significant signals for
schizophrenia, the chromosome 10q24 variants exhibiting strongest
evidence for association are in non-coding sequence [Schizophrenia
Working Group of the Psychiatric Genomics Consortium, 2014].
These variants do not appear to index variation influencing protein
structure, and are therefore likely to confer risk for schizophrenia
through effects on the expression of one or more genes in the
region. Measures of allele-specific expression provide a powerful
means of assessing such cis-regulatory influences, because they allow
the level of gene expression fromchromosomes carrying the risk and
non-risk alleles of a given variant to be compared simultaneously
within individual samples [Bray et al., 2003a]. This approach
typically makes use of exonic (i.e., expressed) single nucleotide
polymorphisms (SNPs) in genes of interest as allele-specific tags,
allowing theRNAtranscribed fromeachparental chromosome tobe
distinguished and relatively quantified in individual heterozygotes
[Yan et al., 2002]. Amajor advantage of thismethod over traditional
expression quantitative trait loci (eQTL) approaches based on totalFIG. 1. Genetic association with schizophrenia in a region of strong linka
by Ricopili (http://www.broadinstitute.org/mpg/ricopili/) using the PGC_SC
the Psychiatric Genomics Consortium [2014] study. Positions of rs1119
of genome-wide significance (P< 5 108) is indicated by a green horiz
showing most significant association with schizophrenia (rs11191419) a
online version of this article, available at http://wileyonlinelibrary.com/jogene expression is that it effectively controls for tissue variables such
as RNA quality as well as confounding effects of other genetic and
environmental variables, since these influences will usually act on
both alleles to the same extent [Bray et al., 2003b].
In order to identify genes that are differentially cis-regulated in
associationwith schizophrenia risk variants on chromosome 10q24
(and therefore genes at the locus that potentially confer suscepti-
bility to the disorder), we assessed genotypic effects on the
allele-specific expression of the genes encompassed by the strongest
schizophrenia association signal: BORCS7 (formerly C10ORF32),
AS3MT, CNNM2, and NT5C2 (Fig. 1). As cis-effects on gene
expression can be specific to developmental stage [Hill and
Bray, 2012; Tao et al., 2014] and brain region [Buonocore et al.,
2010; Gibbs et al., 2010; Ramasamy et al., 2014], we examined
effects in the human fetal brain as well as in three adult brain
regions implicated in the pathophysiology of schizophrenia: dor-
solateral prefrontal cortex (DLPFC), hippocampus, and caudate.
MATERIALS AND METHODS
Brain Samples
Ethical approval for this study was provided by The Joint South
London and Maudsley and The Institute of Psychiatry NHS
Research Ethics Committee (REF: PNM/12/13-102). Post-mortem
human brain tissue from 116 unrelated adults (mean age at death:
72 years; range: 18–102 years) was obtained from the London
Neurodegenerative Diseases Brain Bank (UK). All subjects were
free from psychiatric or neurological diagnosis at the time of
death. Whole brain from 95 second trimester human fetusesge disequilibrium on chromosome 10q24.32-q24.33. Plot generated
Z52_may13 dataset described in the Schizophrenia Working Group of
1419 and ch10_104957618_I are indicated by triangles. The threshold
ontal line. Color key indicates r2 between the variant at the locus
nd other variants in the region. [Color figure can be seen in the
urnal/ajmgb]
DUARTE ET AL. 3(13–23 post-conception weeks) was provided by the MRC—
Wellcome Trust Human Developmental Biology Resource (UK).
The demographics of samples assayed for each candidate gene are
provided in Supplementary Table S1. Genomic DNA was initially
extracted from all samples using standard phenol/chloroform
procedures, and was used to genotype for the schizophrenia risk
variants and the exonic SNPs used to assay the allele-specific
expression of each gene. Total RNA was extracted from each
brain sample using Tri-Reagent (Life Technologies, Paisley, UK),
according to manufacturer’s instructions. RNA samples were
treated with TURBO DNase (Life Technologies) prior to reverse
transcription and did not yield a PCR product in the absence of a
reverse transcription step. Approximately 1mg of total RNA was
reverse transcribed with SuperScript III and randomdecamers (Life
Technologies). Resulting cDNA was diluted 1:7 prior to use.Genotyping
In order to identify heterozygotes informative for the allele-specific
expression assays, all samples were initially genotyped for the exonic
(expressed) SNPs rs4917985, rs1046778, rs2275271, and rs3740387,
tagging BORCS7, AS3MT, CNNM2, and NT5C2 transcripts, respec-
tively.Genotypingof exonic SNPswas performedby single base primer
extension using SNaPshot1 chemistry (Life Technologies). All 116
adult and 95 fetal samples were also genotyped for schizophrenia risk
SNP rs11191419 and indel ch10_104957618_I (rs202213518). These
were selected for study because they are the two independent (r2< 0.2)
variants at the chromosome 10q24 locus showing most significant
association with schizophrenia (rs11191419, P¼ 6.2 1019;
ch10_104957618_I, P¼ 1.06 1013) in the largest GWAS of the
disorder published to date [Schizophrenia Working Group of the
Psychiatric Genomics Consortium, 2014] (Fig. 1). SNP rs11191419
was genotyped by single base primer extension using SNaPshot1
chemistry (Life Technologies). The ch10_104957618_I indel was gen-
otyped by Sanger sequencing using BigDye Terminator v3.1 (Life
Technologies) in the forward and reverse direction. Primer sequences
areprovided inSupplementaryTable S2.Wehadpreviously genotyped
all adult samples for rs7085104 and rs11191580, two chromosome
10q24 SNPs reported as genome-wide significant in earlier GWAS of
schizophrenia [Schizophrenia Psychiatric Genome-Wide Association
Study Consortium, 2011; Ripke et al., 2013], using SNaPshot1 primer
extension (Life Technologies). SNP rs7085104 is in strong linkage
disequilibrium (LD)with rs11191419 in our samples (r2¼ 0.79), while
SNP rs11191580 is in strong LD with ch10_104957618_I (r2¼ 0.82),
suggesting that they index the same functional risk variation.Therewas
no significant (P< 0.05) deviation fromHardy-Weinberg equilibrium
in the genotype distribution of any of the genotyped variants.Assessment of Allele-Specific Expression
To investigate variable cis-effects on the expression of genes at the
chromosome 10q24 locus, we used a common exonic SNP in each
gene to distinguish the RNA transcribed from each chromosomal
copy. Expressed SNPs rs4917985, rs1046778, rs2275271, and
rs3740387 were used to tag RNA transcripts for BORCS7,
AS3MT, CNNM2, and NT5C2, respectively. The allele-specific
expression assay was performed using brain cDNA alongside thecorresponding genomic DNA from the same subjects. Sequences
containing the exonic tag SNPs were PCR-amplified using primers
based on single exon sequence, each producing the same amplicon
from both cDNA and genomic DNA (Supplementary Table S2).
Four technical replicates for each cDNA and genomic DNA sample
were assayed for each expressed SNP, with one H2O-negative
control on each plate. PCR products were treated with shrimp
alkaline phosphatase and exonuclease I (New England Biolabs,
Hitchin, UK) to inactivate nucleotides and primers for down-
stream steps. Alleles of each expressed SNP were discriminated
and relatively quantified by SNaPshot1 primer extension (Life
Technologies) using extension primers detailed in Supplementary
Table S2. Reaction products were electrophoresed on an Applied
Biosystems 3130xl Genetic Analyzer and peak heights of allele-
specific extended primers were determined using GeneMarker
software (SoftGenetics, State College, PA). Peak heights represent-
ing the relative abundance of each allele were used to calculate an
allele ratio for each reaction. Allele ratios were calculated for each
expressed SNP by dividing peak height for the expressed allele
that is usually in phase with the risk alleles of rs11191419/
ch10_104957618_I by the peak height of the expressed allele
that is usually in phase with the non-risk alleles of these variants
in samples that were heterozygous at the expressed SNP and the risk
variant. For each plate, the average allele ratio from all genomic
DNA samples was used as a correction factor for all genomic DNA
and cDNA allele ratios, since this can be assumed to reflect a perfect
1:1 ratio of the two alleles and can therefore be used to correct for
any inequalities in allelic representation specific to the assay [Bray
et al., 2003b]. The average of the four corrected allele ratios for
genomic DNA and cDNA from each sample was calculated
and used for statistical comparisons. Any samples showing poor
reproducibility in cDNA allele ratios (standard deviation/mean
> 0.25) were excluded from further analyses.
Assessment of Association Between Schizophrenia
Risk Alleles and Allele-Specific Expression
Predicted haplotypes between the schizophrenia risk variants
(rs11191419 and ch10_104957618_I) and the expressed SNP for
each gene were calculated based on combined genotype data from
the 116 adult and 95 fetal samples using Haploview 4.2 software
[Barrett et al., 2005]. Predicted haplotype frequencies were
used to infer phase between the risk alleles of rs11191419/
ch10_104957618_I and the alleles of the exonic SNPs, so that
the effect of the risk alleles on gene expression (i.e., up- or down-
regulation) could be determined, as described previously [Bray
et al., 2005]. Specifically, for samples that were heterozygous at
both the exonic SNP and a risk variant, we calculated the frequency
of the two possible diplotypes constructed from the two alleles of
the exonic SNP and the two alleles of the risk variant on the basis
of predicted haplotype frequencies and the assumption of Hardy
Weinberg equilibrium using the equations:
Frequency diplotype 1 ¼ 2 f requency haplotype A f requency haplotype B
Frequency diplotype 2 ¼ 2 f requency haplotype C f requency haplotype D
The probability that an individual who is heterozygous at both the
exonic SNP and the risk variant is carrying diplotype 1 (comprising
4 AMERICAN JOURNAL OF MEDICAL GENETICS PART Bhaplotypes A and B, rather than haplotypes C and D) is, therefore,
calculated by dividing the predicted frequency of diplotype 1 by
the combined frequency of both possible diplotypes.
Due to strong linkage disequilibrium in the region, the risk
alleles of rs11191419 and ch10_104957618_I would nearly always
be carried on the same chromosome as one of the alleles of each
exonic SNP. As an initial test of whether the risk alleles were
associated with a relative increase or decrease in the allelic expres-
sion of each gene, we therefore compared cDNA allele ratios in
samples that were heterozygous for each risk variant (where the risk
alleles would usually be carried on the same chromosome as one of
the expressed alleles and the non-risk alleles would be usually
carried on the same chromosome as the alternative expressed allele)
with the allele ratios observed in genomicDNA (representing a true
1:1 ratio of the two alleles). As a more specific test of whether risk
genotype could account for altered cis-regulation of each candidate
gene, we also compared cDNA allele ratios between risk allele
heterozygotes (where any cis-regulatory effects of that variant will
differ) and homozygotes (where any cis-regulatory effects of the
variant will be the same), as performed previously [Bray et al.,
2003a, 2005; Hill and Bray, 2012]. Due to small numbers of
homozygotes for rs11191419 in assayed exonic heterozygotes,
these latter analyses were restricted to comparisons between
ch10_104957618_I genotypes. All comparisons were performed
by t-tests using SPSS 22.0 software. Where differences in variance
were detected between comparison groups (Levene’s test P< 0.05),
we used t-tests that assumed unequal variance. All tests were two-
tailed and P-values < 0.05 were considered to be significant. As a
more stringent measure of the significance of each finding, we
additionally applied a Bonferroni correction for the number of tests
performed in each analysis. For the comparisions between allele
ratios in cDNA from risk allele heterozygotes and those in genomic
DNA, we corrected observed P-values for 32 tests (assessing the
effects of heterozygosity at two risk variants on the allelic expres-
sion of four genes in four brain tissues). For the comparisons
between cDNA ratios observed in heterozygotes and homozygotes
for ch10_104957618_I, we corrected observed P-values for 16 tests
(assessing the effect of ch10_104957618_I genotype on four genes
in four brain tissues).RESULTS
One hundred and sixteen adult and 95 fetal human brains were
initially genotyped for schizophrenia risk SNP rs11191419
and indel ch10_104957618_I (rs202213518), as well as exonic
SNPs in BORCS7 (rs4917985), AS3MT (rs1046778), CNNM2
(rs2275271), and NT5C2 (rs3740387), which could serve as
allele-specific tags for the four candidate genes in heterozygous
samples. Frequencies of the schizophrenia risk alleles in our
samples approximated those observed in the control sample of
the recent Schizophrenia Working Group of the Psychiatric
Genomics Consortium [2014] GWAS. The risk (T) allele of
rs11191419 had a reported frequency of 0.64 in the GWAS
control samples and a frequency of 0.64 in our combined fetal
and adult brain samples, while the risk (deletion) allele of
ch10_104957618_I had a reported frequency of 0.92 in the
GWAS control samples and a frequency of 0.90 in our samples.Predicted haplotype frequencies in our entire brain collection
allowed us to infer phase between the risk alleles of rs11191419/
ch10_104957618_I and the alleles of the exonic SNPs used to assess
the allelic expression of each candidate gene (see Materials and
Methods). The strong linkage disequilibrium (D0) in the region
meant that, in individuals who were heterozygous at a risk variant
as well as an exonic variant, the risk allele would nearly always be
carried on the same chromosome as a particular allele of the exonic
SNP. An assessment of whether the risk alleles were associated with
a general increase or decrease in the allelic expression of each
candidate gene could, therefore, be made by comparing cDNA
allele ratios in individuals who were heterozygous for the risk
variant with allele ratios observed in genomic DNA (representing
the true 1:1 ratio of the two alleles) [e.g., Bray et al., 2003a, 2005].
Allelic expression data at SNP rs4917985, used to tagBORCS7, in
heterozygotes for rs11191419 and ch10_104957618_I, are shown in
Figure 2A. The C-allele of rs4917985 was predicted to be in phase
with the risk (T-) allele of rs11191419 on>99% of occasions when
the subject was heterozygous at both loci. Allele ratios in cDNA
from rs11191419 heterozygotes indicated a mean increase in
expression of the allele carried on the same chromosome as the
risk allele, relative to that carried with the non-risk allele, in all
assayed tissues (DLPFC: 12%, hippocampus: 8%, caudate: 11%,
fetal brain 5%). cDNA allele ratios in all assayed tissues differed
significantly from allele ratios observed in genomic DNA (all
P< 0.05). Although P-values survived Bonferroni correction for
32 independent tests only in the DLPFC (P¼ 0.001, corrected
P¼ 0.032), BORCS7 cDNA ratios did not differ significantly from
those obtained from rs11191419 heterozygotes in any other adult
brain region (all P> 0.05). The C-allele of rs4917985 was also
predicted to be in phase with the risk (deletion) allele of
ch10_104957618_I on >99% of occasions when the subject was
heterozygous at both loci. However, allele ratios in cDNA from
ch10_104957618_I heterozygotes were close to the 1:1 ratio of
equal allelic expression, and did not significantly differ from those
observed in genomic DNA in any tissue.
Allelic expression data at SNP rs1046778, used to tag AS3MT,
in heterozygotes for rs11191419 and ch10_104957618_I, are
shown in Figure 2B. The T-allele of rs1046778 was predicted
to be in phase with the risk (T-) allele of rs11191419 on>94% of
occasions when the subject was heterozygous at both loci. As for
BORCS7, cDNA allele ratios in rs11191419 heterozygotes indi-
cated a mean increase in expression of the AS3MT allele carried
on the same chromosome as the risk allele, compared to that
carried with the non-risk allele, in all assayed tissues (DLPFC:
14%, hippocampus: 36%, caudate: 23%, fetal brain 40%). cDNA
allele ratios differed significantly from allele ratios observed in
genomic DNA in fetal brain and in adult hippocampus and
caudate (P< 0.05 in all tissues). Although P-values survived
Bonferroni correction for 32 independent tests only in fetal brain
(P¼ 1.12 105, corrected P¼ 0.00036), AS3MT cDNA ratios
did not differ significantly from those observed in rs11191419
heterozygotes in adult hippocampus or caudate (P> 0.05). The
T-allele of rs1046778 was predicted to be in phase with the risk
(deletion) allele of ch10_104957618_I on >99% of occasions
when the subject was heterozygous at both loci. Relative over-
expression of the AS3MT allele in phase with the risk allele was
FIG. 2. Allelic expression of BORCS7 (A), AS3MT (B), CNNM2 (C), and NT5C2 (D) in heterozygotes for schizophrenia risk variants rs11191419
and ch10_104957618_I. Allelic expression ratios are calculated by dividing measures of the expressed allele that is generally in phase with
the schizophrenia risk alleles by measures of the expressed allele that is generally in phase with the non-risk alleles for each susceptibility
variant. All raw cDNA ratios are divided by the average allele ratio in genomic DNA (representing the true 1:1 allele ratio) to correct for any
inequalities in allelic representation specific to each assay. Data points represent the average of four corrected measures of cDNA allele ratio
per sample. Mean corrected cDNA allele ratios are indicated by horizontal lines. The dotted horizontal line indicates the mean genomic DNA
(1:1) ratio of the two alleles. Comparisons between cDNA allele ratios in heterozygotes for the risk variants and allele ratios in genomic
DNA: < 0.05, P< 0.05 when Bonferroni corrected for 32 tests.
DUARTE ET AL. 5less pronounced than in rs11191419 heterozygotes (DLPFC: 7%,
hippocampus: 24%, caudate: 14%, fetal brain 14%). While allele
ratios in ch10_104957618_I heterozygotes differed significantly
between cDNA and genomic DNA in hippocampus, caudate and
fetal brain (all P< 0.05), no observation survived Bonferroni
correction.Allelic expression data at SNP rs2275271, used to tagCNNM2, in
heterozygotes for rs11191419 and ch10_104957618_I, are shown in
Figure 2C. The A-allele of rs2275271 was predicted to be in phase
with the risk (T-) allele of rs11191419 on>98% of occasions when
the subject was heterozygous at both loci. However, unlike cDNA
allele ratios in rs11191419 heterozygotes for BORCS7 and AS3MT,
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expression, only differing significantly from those in genomic
DNA in fetal brain (P¼ 0.012), where a small (5%) relative
decrease in the mean expression of the allele generally in phase
with the risk allele of rs11191419 was observed. The A-allele of
rs2275271 was predicted to be in phase with the risk (deletion)
allele of ch10_104957618_I on >99% of occasions when the
subject was heterozygous at both loci. Heterozygotes for
ch10_104957618_I also displayed little allelic expression imbalance
of CNNM2, with cDNA allele ratios only differing significantly
from those in genomic DNA in the adult DLPFC, where amean 5%
decrease in expression of the allele usually in phase with the risk
allele was observed (P¼ 0.015). No allelic expression imbalance of
CNNM2 associated with heterozygosity for the assayed schizo-
phrenia risk variants survived Bonferroni correction.
Allelic expression data at SNP rs3740387, used to tag NT5C2, in
heterozygotes for rs11191419 and ch10_104957618_I, are shown in
Figure 2D. The C-allele of rs3740387 was predicted to be in phase
with the risk (T-) allele of rs11191419 on>98% of occasions when
the subject was heterozygous at both loci. In rs11191419 hetero-
zygotes, expression of the NT5C2 allele generally in phase with the
risk allele was reduced in all assayed adult brain regions (mean
DLPFC: 11%, hippocampus: 7%, caudate: 7%), with cDNA allele
ratios differing significantly from those in genomic DNA (all
P< 0.05). Observed P-values survived Bonferroni correction for
32 independent tests in theadultDLPFC(P¼ 6.29 107, corrected
P¼ 2.01 105) and caudate (P¼ 0.001, correctedP¼ 0.032),with
a less significant imbalance of allelic expression observed in the
hippocampus (P¼ 0.003, corrected P¼ 0.083). The C-allele of
rs3740387 was predicted to be in phase with the risk (deletion)
allele of ch10_104957618_I on>99% of occasions when the subject
was heterozygous at both loci. Expression of the NT5C2 allele in
phase with the ch10_104957618_I risk allele was also reduced in all
assayed adult brain regions (mean DLPFC: 15%, hippocampus:
12%, caudate: 13%), with highly significant differences in allele
ratios observed between cDNA and genomic DNA that survived
Bonferroni correction in all areas (DLPFC: P¼ 1.03 104, cor-
rected P¼ 0.003; hippocampus: P¼ 2.64 106, corrected
P¼ 8.46 105; caudate P¼ 8.11 105, corrected P¼ 0.0025).
Unlike cDNA ratios in rs11191419 heterozygotes, those in
ch10_104957618_I heterozygotes also significantly differed from
genomic DNA in fetal brain (P¼ 0.05), with the risk allele again
associated with reduced NT5C2 allelic expression, although this
latter observation did not survive Bonferroni correction.
Although comparisons between cDNA and gDNA allele ratios in
heterozygous risk allele carriers under conditions of high-linkage
disequilibrium allow an assessment of whether the risk allele is
associated with a general increase or decrease in allelic expression
[Bray et al., 2003a, 2005;Hill andBray, 2012], theydonot specifically
test whether genotype at the risk variant could directly account for
altered cis-regulation of the gene. For this, it is necessary to compare
cDNA allele ratios in heterozygotes for the risk variant (where any
cis-regulatory effects of the two alleles will differ) with those in
homozygotes for the risk variant (where any cis-regulatory effects of
the variant will be equal) [Bray et al., 2003a, 2005; Williams et al.,
2011;Hill andBray, 2012]. Small genotypegroupsprecludedsuchan
assessment of cis-regulatory effects of rs11191419, but genotype atch10_104957618_I was associated with significant effects on the
allelic expression of BORCS7 in fetal brain, adult DLPFC, adult
hippocampus and adult caudate, AS3MT in the fetal brain and
adult caudate, and NT5C2 in the fetal brain, adult DLPFC and
adult hippocampus. P-values survived Bonferroni correction for 16
tests for BORCS7 in the adult hippocampus (P¼ 0.001, corrected
P¼ 0.016) and fetal brain (P¼ 0.002, corrected P¼ 0.032), AS3MT
in the fetal brain (P¼ 0.002, correctedP¼ 0.032), andNT5C2 in the
adult DLPFC (P¼ 0.003, corrected P¼ 0.048). Mean cDNA allele
ratios at the four candidate genes in ch10_104957618_I heterozy-
gotes and homozygotes are shown in Table I. These analyses showed
that the risk allele of ch10_104957618_I is associated with a down-
regulation of both BORCS7 and AS3MT, reducing the general
overexpression of these genes associated with the risk allele of
rs11191419, with less allelic expression imbalance observed in
heterozygotes for ch10_104957618_I than in homozygotes.
This is consistent with the initial comparisons between allele ratios
in cDNA and genomic DNA, which showed less pronounced
allelic expression imbalance of BORCS7 and AS3MT in
ch10_104957618_Iheterozygotes than in rs11191419heterozygotes.
In contrast, the risk alleles of rs11191419 and ch10_104957618_I
appear both to be associated with reduced expression of NT5C2.
Indeed, genotype at rs11191419 and ch10_104957618_I could
largely account for observed allelic expression imbalance of
NT5C2 in the adult DLPFC (Fig. 3), where samples that were
heterozygous at both risk loci showed a mean 16% reduction in
NT5C2 allelic expression, while homozygotes at both risk loci
displayed cDNA allele ratios close to the genomic 1:1 ratio (com-
parison between cDNA ratios in heterozygotes and homozygotes at
both loci: P¼ 0.007).DISCUSSION
Variants on chromosome 10q24.32-q24.33 exhibit robust associa-
tion with schizophrenia [Schizophrenia Psychiatric Genome-Wide
Association Study Consortium, 2011; Aberg et al., 2013; Ripke
et al., 2013; Schizophrenia Working Group of the Psychiatric
Genomics Consortium, 2014], but, like many regions implicated
by GWAS, the actual susceptibility genes cannot be easily resolved
through genetic data alone. Using a highly sensitive method for
assessing variable cis-effects on gene expression [Yan et al., 2002;
Bray et al., 2003a,b], we have found that several of the principal
candidate genes at this locus exhibit altered cis-regulation in the
developing and adult human brain in association with the most
strongly supported schizophrenia risk variants. Largest and most
consistent effects were observed on BORCS7, AS3MT, andNT5C2,
providing functional support for these as genuine susceptibility
genes for schizophrenia.
Our data indicate a complex pattern of cis-regulation at
the chromosome 10q24 locus. The indel ch10_104957618_I
(rs202213518) is located 4,555 bp upstream of the predicted tran-
scription start site of NT5C2 transcript variant 1 (NM_012229).
ENCODEChIP-seq data indicate that ch10_104957618_I resides in
an H3K27ac-marked region that is bound by multiple transcrip-
tion factors, suggesting direct effects of this variant on NT5C2
transcription. However, genotype at this variant was also found to
influence the allelic expression of BORCS7 and AS3MT, with the
TABLE I. Average Corrected cDNA Allele Ratios at Expressed SNPs in BORCS7, AS3MT, CNNM2, and NT5C2 According to Genotype at
Schizophrenia Risk Variant ch10_104957618_I
Gene (expressed SNP) Genotype at ch10_104957618_I Adult DLPFC Adult hippocampus Adult caudate Fetal whole brain
BORCS7 (rs4917985; C/Ta) Heterozygous 0.99 0.95 0.98 0.99
Homozygous 1.17 1.12 1.15 1.06
P het versus hom 0.006 0.001 0.004 0.002
AS3MT (rs1046778; T/C) Heterozygous 1.07 1.24 1.14 1.14
Homozygous 1.25 1.52 1.31 1.42
P het versus hom 0.235 0.187 0.034 0.002
CNNM2 (rs2275271; A/G) Heterozygous 0.95 0.96 1.04 0.98
Homozygous 0.99 0.98 1.02 0.95
P het versus hom 0.095 0.629 0.527 0.342
NT5C2 (rs3740387; C/T) Heterozygous 0.85 0.88 0.87 0.93
Homozygous 0.94 0.95 0.93 0.99
P het versus hom 0.003 0.014 0.072 0.016
aAllele ratios at each expressed SNP were calculated by dividing measures of the allele generally in phase with the schizophrenia risk alleles by measures of the allele generally in phase with the non-risk
alleles, as indicated.
P-values surviving Bonferroni correction for 16 tests.
Uncorrected P-values < 0.05 are indicated in bold.
DUARTE ET AL. 7risk allele (in contrast to that of rs11191419) associated with
reduced allelic expression of these genes. Similarly, heterozygosity
for rs11191419, located within 2 kb of the transcriptional start site
of BORCS7, was found to be associated with allelic expressionFIG. 3. Allele ratios at expressed NT5C2 SNP rs3740387 in the
DLPFC of adult subjects who are homozygous at both
rs11191419 and ch10_104957618_I (6 M, 3 F, average age¼ 64
years) and in adult subjects who are heterozygous at both
variants (9 M, 4 F, average age¼ 70 years). Data points
represent the average of four corrected measures of allele ratio
in genomic DNA or cDNA per sample. Mean corrected allele ratios
are indicated by horizontal lines. The dotted horizontal line
indicates the mean genomic DNA (1:1) ratio of the two alleles.
Allele ratios in cDNA from subjects who are homozygous at both
risk variants do not significantly differ from those in genomic
DNA. Allele ratios in cDNA from subjects who are heterozygous
at both risk variants differ significantly from those in genomic
DNA and from those in cDNA from homozygotes at both
variants. < 0.01, P< 0.001.imbalance ofBORCS7,AS3MT, andNT5C2. This could result from
long-range enhancer effects of these variants (or variants in linkage
disequilibrium with them), transcriptional interference on adja-
cent gene expression, or linkage disequilibrium with other func-
tional variants at the chromosome 10q24 locus.
It appears that the risk alleles of rs11191419 and
ch10_104957618_I have opposing effects on the expression of
both BORCS7 and AS3MT, with the risk (T-) allele of rs11191419
associated with increased allelic expression and the risk (deletion)
allele of ch10_104957618_I associated with decreased allelic expres-
sion of these genes. This is consistent with the risk allele of
ch10_104957618_I conferring susceptibility to schizophrenia
through effects on a different gene, such as NT5C2. However, the
risk allele of ch10_104957618_I appears insufficient to fully coun-
teract the increased expression of AS3MT associated with the
risk allele of rs11191419, with allele ratios in cDNA from
ch10_104957618_I heterozygotes remaining significantly higher
than the genomic 1:1 ratio in most assayed tissues. In contrast,
both risk alleles of rs11191419 and ch10_104957618_I are associated
with reduced allelic expression ofNT5C2, and appear to account for
the majority of cis-regulatory effects on this gene observed in the
adult DLPFC. It is possible that the strong association between
rs11191419 and schizophrenia is due to it indexing functional risk
variation affecting the regulation of multiple genes at the locus.
Although only some observations survived Bonferroni correc-
tion for multiple testing, we urge caution in drawing conclusions
as to the relative importance of each finding on the basis of
P-values alone, since the number of subjects differed between
analyses due to differences in expressed allele frequency between
candidate genes and the availability of brain tissue from each
region. As can be seen in Figure 2, for BORCS7, AS3MT, and
NT5C2 at least, we observed a general consistency in the effects of
risk variant heterozygosity on allelic expression across the brain
tissues analyzed.
8 AMERICAN JOURNAL OF MEDICAL GENETICS PART BThere are no previous data assessing the impact of
ch10_104957618_I genotype on gene expression. However, our
findings for rs11191419 appear consistent with existing data gen-
erated by eQTL and bioinformatic approaches. The Schizophrenia
Working Group of the Psychiatric Genomics Consortium study
[2014] included analyses that sought to relate credible GWAS risk
variants to genome-wide eQTL data, finding rs11191419 to be in
strong linkage disequilibrium (r2¼ 0.85) with an eQTL SNP
(rs7096169) influencingAS3MT expression in blood. Using several
brain eQTL datasets, Roussos et al. [2014] identified SNPs influ-
encing BORCS7 (C10ORF32), AS3MT, WBP1L, and NT5C2
expression that are in linkage disequilibrium with rs7085104,
identified in an earlier GWAS of schizophrenia [Ripke et al.,
2013], which we found to be in strong linkage disequilibrium
(r2¼ 0.79)with rs11191419 in the samples genotyped in the present
study. These authors also assessed whether schizophrenia-
associated eQTLs were located in predicted cis-regulatory elements
(CREs); expression of BORCS7 and AS3MT was reported to be
influenced by SNPs within individual CRE, while expression of
NT5C2 was associated with SNPs in 14 such elements [Roussos
et al., 2014]. Most recently, a genome-wide analysis of DNA
methylation QTL in the human fetal brain has indicated that
rs7085104 and SNPs in linkage disequilibrium with it are QTL
for methylation probes within AS3MT [Hannon et al., 2016],
consistent with our observation of a large allelic expression imbal-
ance of AS3MT in association with rs11191419 heterozygosity in
the fetal brain.
Our study is the first to specifically explore effects of chromo-
some 10q24 schizophrenia risk variants on gene expression in the
human fetal brain. Microarray data indicate that AS3MT and
NT5C2 are both expressed at a higher level in the prenatal human
brain compared to that of the adult [Kang et al., 2011; Birnbaum
et al., 2015]. We find that heterozygosity for rs11191419 is
associated with particularly pronounced allelic expression
imbalance of AS3MT in the fetal brain, with an average 40%
increase in expression of the AS3MT allele that is generally
carried on the same chromosome as the risk allele. We find
no evidence that NT5C2 expression is influenced by rs11191419
genotype in fetal brain, but we do observe small effects of
ch10_104957618_I genotype on NT5C2 allelic expression at
this early stage of development. These findings would therefore
appear consistent with an early neurodevelopmental component
to schizophrenia [Murray and Lewis, 1987; Weinberger, 1987],
although the observed persistence of effects in the adult brain
suggests an ongoing risk mechanism.
A limitation of our study is that it focused on a restricted number
of positional candidate genes at the chromosome 10q24.32-q24.33
locus. Although we selected the four candidates flanked by the two
best supported risk variants (Fig. 1), extended linkage disequilib-
rium and the possibility of long-range effects on gene regulation
[Sanyal et al., 2012] implicate several other known genes in the
region (e.g.,WBP1L,CYP17A1, INA,PCGF6). In addition, through
our use of exonic SNPs that typically tag multiple alternative
transcripts of a given gene, we might underestimate cis-regulatory
effects on individual transcripts, while missing effects on any
transcripts that do not include those SNPs. Some of these limi-
tations could be overcome by RNA sequencing, which can be usedto measure allele-specific (as well as total) expression of individual
transcripts on a genome-wide scale.
The neural functions of the genes implicated in this study remain
to be fully elucidated. BORCS7 encodes BLOC-1-related complex
subunit 7 (Diaskedin), part of the recently described BLOC-1-
related complex, which has been implicated in lysosomal function
and cell migration [Pu et al., 2015]. AS3MT encodes arsenic
methyltransferase, which has a known role in arsenic metabolism
[Sumi and Himeno, 2012], although its functions in the brain are
currentlyunclear.NT5C2 encodesa cytosolicpurine50-nucleotidase
(cytosolic 50-nucleotidase II, or cN-II) involved in cellular purine
metabolism [Itoh, 2013]. A purinergic hypothesis of schizophrenia
has been proposed to explain neurochemical as well as neuro-
developmental aspects of the disorder [Lara and Souza, 2000].
In summary, we have provided an assessment of cis-regulatory
effects associated with schizophrenia risk variants in a region of
extensive linkage disequilibrium on chromosome 10q24. We re-
port altered cis-regulation of BORCS7, AS3MT, and NT5C2 in
association with schizophrenia risk variation, implicating these as
genuine schizophrenia susceptibility genes at the locus. Further
characterization of these genes in the developing and adult brain is
now warranted in order to understand how perturbations in their
expression might confer risk for schizophrenia.ACKNOWLEDGMENTS
This work was funded by a Science without Borders (Brazil)
scholarship to R.R.R. Duarte (CAPES BEX 1279-13-0) and a
Medical Research Council (UK) Research Grant to N.J. Bray (grant
#G0802166). The human fetal material was provided by the Joint
MRC/Wellcome Trust (grant #099175/Z/12/Z) Human Develop-
mental Biology Resource (www.hdbr.org). Adult tissue samples
were supplied by The London Neurodegenerative Diseases Brain
Bank, which receives funding from the MRC and, as part of the
Brains for Dementia Research programme, jointly funded by
Alzheimer’s Research UK and Alzheimer’s Society.REFERENCES
Aberg KA, Liu Y, Bukszar J, McClay JL, Khachane AN, Andreassen OA,
BlackwoodD, Corvin A,Djurovic S, GurlingH,Ophoff R, Pato CN, Pato
MT, Riley B, Webb T, Kendler K, O’Donovan M, Craddock N, Kirov G,
Owen M, Rujescu D, St. Clair D, Werge T, Hultman CM, Delisi LE,
Sullivan P, van den Oord EJ. 2013. A comprehensive family-based
replication study of schizophrenia genes. JAMA Psychiatry 70:573–581.
Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: Analysis and
visualization of LD and haplotype maps. Bioinformatics 21:263–265.
Birnbaum R, Jaffe AE, Chen Q, Hyde TM, Kleinman JE, Weinberger DR.
2015. Investigation of the prenatal expression patterns of 108 schizo-
phrenia-associated genetic loci. Biol Psychiatry 77:e43–e51.
Bray NJ, Buckland PR, Williams NM, Williams HJ, Norton N, Owen MJ,
O’Donovan MC. 2003a. A haplotype implicated in schizophrenia sus-
ceptibility is associated with reduced COMT expression in human brain.
Am J Hum Genet 73:152–161.
Bray NJ, Buckland PR, Owen MJ, O’Donovan MC. 2003b. Cis-acting
variation in the expression of a high proportion of genes in human brain.
Hum Genet 113:149–153.
DUARTE ET AL. 9Bray NJ, Preece A, Williams NM, Moskvina V, Buckland PR, Owen MJ,
O’DonovanMC. 2005. Haplotypes at the dystrobrevin binding protein 1
(DTNBP1) gene locus mediate risk for schizophrenia through reduced
DTNBP1 expression. Hum Mol Genet 14:1947–1954.
Buonocore F, HillMJ, Campbell CD, Oladimeji PB, Jeffries AR, Troakes C,
Hortobagyi T, Williams BP, Cooper JD, Bray NJ. 2010. Effects of cis-
regulatory variation differ across regions of the adult human brain. Hum
Mol Genet 19:4490–4496.
Cross-Disorder Group of the Psychiatric Genomics Consortium. 2013.
Identification of risk loci with shared effects on five major psychiatric
disorders: A genome-wide analysis. Lancet 381:1371–1379.
Gibbs JR, van der BrugMP, Hernandez DG, Traynor BJ, Nalls MA, Lai SL,
Arepalli S, Dillman A, Rafferty IP, Troncoso J, Johnson R, Zielke HR,
Ferrucci L, Longo DL, Cookson MR, Singleton AB. 2010. Abundant
quantitative trait loci exist for DNA methylation and gene expression in
human brain. PLoS Genet 6:e1000952.
Hannon E, Spiers H, Viana J, Pidsley R, Burrage J,Murphy TM, Troakes C,
Turecki G, O’Donovan MC, Schalkwyk LC, Bray NJ, Mill J. 2016.
Methylation QTLs in the developing brain and their enrichment in
schizophrenia risk loci. Nat Neurosci 19:48–54.
Hill MJ, Bray NJ. 2012. Evidence that schizophrenia risk variation in the
ZNF804A gene exerts its effects during fetal brain development. Am J
Psychiatry 169:1301–1308.
Itoh R. 2013. Enzymatic properties and physiological roles of cytosolic
50-nucleotidase II. Curr Med Chem 20:4260–4284.
KangHJ, KawasawaYI, Cheng F, ZhuY,XuX, LiM, SousaAM, PletikosM,
Meyer KA, Sedmak G, Guennel T, Shin Y, JohnsonMB, Krsnik Z, Mayer
S, Fertuzinhos S, Umlauf S, Lisgo SN, Vortmeyer A, Weinberger DR,
Mane S, Hyde TM, Huttner A, Reimers M, Kleinman JE, Sestan N. 2011.
Spatio-temporal transcriptome of the human brain. Nature 478:483–
489.
Lara DR, Souza DO. 2000. Schizophrenia: A purinergic hypothesis. Med
Hypotheses 54:157–166.
Murray RM, Lewis SW. 1987. Is schizophrenia a neurodevelopmental
disorder? Br Med J 295:681–682.
Pu J, Schindler C, Jia R, JarnikM, Backlund P, Bonifacino JS. 2015. BORC,
a multisubunit complex that regulates lysosome positioning. Dev Cell
33:176–188.
Ramasamy A, Trabzuni D, Guelfi S, Varghese V, Smith C,Walker R, De T,
UK Brain Expression Consortium, North American Brain Expression
Consortium, Coin L, de Silva R, Cookson MR, Singleton AB, Hardy J,
Ryten M, Weale ME. 2014. Genetic variability in the regulation of
gene expression in ten regions of the human brain. Nat Neurosci
17:1418–1428.
Ripke S, O’Dushlaine C, Chambert K, Moran JL, K€ahler AK, Akterin
S, Bergen SE, Collins AL, Crowley JJ, Fromer M, Kim Y, Lee SH,
Magnusson PK, Sanchez N, Stahl EA, Williams S, Wray NR, Xia K,
Bettella F, Borglum AD, Bulik-Sullivan BK, Cormican P, Craddock N,
de Leeuw C, Durmishi N, Gill M, Golimbet V, Hamshere ML,
Holmans P, Hougaard DM, Kendler KS, Lin K, Morris DW, Mors
O, Mortensen PB, Neale BM, O’Neill FA, Owen MJ, Milovancevic MP,
Posthuma D, Powell J, Richards AL, Riley BP, Ruderfer D, Rujescu
D, Sigurdsson E, Silagadze T, Smit AB, Stefansson H, Steinberg S,
Suvisaari J, Tosato S, Verhage M, Walters JT, Multicenter Genetic
Studies of Schizophrenia Consortium, Levinson DF, Gejman PV,
Kendler KS, Laurent C, Mowry BJ, O’Donovan MC, Owen MJ, Pulver
AE, Riley BP, Schwab SG, Wildenauer DB, Dudbridge F, Holmans P,
Shi J, Albus M, Alexander M, Campion D, Cohen D, Dikeos D,
Duan J, Eichhammer P, Godard S, Hansen M, Lerer FB, Liang
KY, Maier W, Mallet J, Nertney DA, Nestadt G, Norton N, O’Neill FA,
Papadimitriou GN, Ribble R, Sanders AR, Silverman JM, Walsh D,
Williams NM, Wormley B, Psychosis Endophenotypes InternationalConsortium, Arranz MJ, Bakker S, Bender S, Bramon E, Collier D,
Crespo-Facorro B, Hall J, Iyegbe C, Jablensky A, Kahn RS, Kalaydjieva
L, Lawrie S, Lewis CM, Lin K, Linszen DH, Mata I, McIntosh A,
Murray RM, Ophoff RA, Powell J, Rujescu D, Van Os J, Walshe M,
Weisbrod M, Wiersma D, Wellcome Trust Case Control Consortium
2, Donnelly P, Barroso I, Blackwell JM, Bramon E, Brown MA, Casas
JP, Corvin AP, Deloukas P, Duncanson A, Jankowski J, Markus HS,
Mathew CG, Palmer CN, Plomin R, Rautanen A, Sawcer SJ, Trembath
RC, Viswanathan AC, Wood NW, Spencer CC, Band G, Bellenguez C,
Freeman C, Hellenthal G, Giannoulatou E, Pirinen M, Pearson RD,
Strange A, Su Z, Vukcevic D, Donnelly P, Langford C, Hunt SE, Edkins
S, Gwilliam R, Blackburn H, Bumpstead SJ, Dronov S, Gillman M,
Gray E, Hammond N, Jayakumar A, McCann OT, Liddle J, Potter SC,
Ravindrarajah R, Ricketts M, Tashakkori-Ghanbaria A, Waller MJ,
Weston P, Widaa S, Whittaker P, Barroso I, Deloukas P, Mathew
CG, Blackwell JM, Brown MA, Corvin AP, McCarthy MI, Spencer CC,
Bramon E, Corvin AP, O’Donovan MC, Stefansson K, Scolnick E,
Purcell S, McCarroll SA, Sklar P, Hultman CM, Sullivan PF. 2013.
Genome-wide association analysis identifies 13 new risk loci for
schizophrenia. Nat Genet 45:1150–1159.
Roussos P, Mitchell AC, Voloudakis G, Fullard JF, Pothula VM, Tsang J,
Stahl EA, Georgakopoulos A, Ruderfer DM, Charney A, Okada Y,
Siminovitch KA, Worthington J, Padyukov L, Klareskog L, Gregersen
PK, Plenge RM, Raychaudhuri S, Fromer M, Purcell SM, Brennand KJ,
Robakis NK, Schadt EE, Akbarian S, Sklar P. 2014. A role for noncoding
variation in schizophrenia. Cell Rep 9:1417–1429.
Sanyal A, Lajoie BR, Jain G, Dekker J. 2012. The long-range interaction
landscape of gene promoters. Nature 489:109–113.
Schizophrenia Psychiatric Genome-Wide Association Study Consortium.
2011. Genome-wide association study identifies five new schizophrenia
loci. Nat Genet 43:969–976.
Schizophrenia Working Group of the Psychiatric Genomics Consortium.
2014. Biological insights from 108 schizophrenia-associated genetic loci.
Nature 511:421–427.
Sumi D, Himeno S. 2012. Role of arsenic (þ3 oxidation state) methyl-
transferase in arsenicmetabolism and toxicity. Biol PharmBull 35:1870–
1875.
Tao R, Cousijn H, Jaffe AE, Burnet PW, Edwards F, Eastwood SL, Shin JH,
LaneTA,WalkerMA,Maher BJ,WeinbergerDR,HarrisonPJ,HydeTM,
Kleinman JE. 2014. Expression of ZNF804A in human brain and alter-
ations in schizophrenia, bipolar disorder, andmajor depressive disorder:
A novel transcript fetally regulated by the psychosis risk variant
rs1344706. JAMA Psychiatry 71:1112–1120.
Weinberger DR. 1987. Implications of normal brain development for the
pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660–669.
Williams HJ, Norton N, Dwyer S, Moskvina V, Nikolov I, Carroll L,
Georgieva L,Williams NM,Morris DW,Quinn EM, Giegling I, IkedaM,
Wood J, Lencz T, Hultman C, Lichtenstein P, Thiselton D, Maher BS,
Molecular Genetics of Schizophrenia Collaboration (MGS) Interna-
tional Schizophrenia Consortium (ISC), SGENE-plus GROUP, Malho-
tra AK, Riley B, Kendler KS, Gill M, Sullivan P, Sklar P, Purcell S,
Nimgaonkar VL, Kirov G, Holmans P, Corvin A, Rujescu D, Craddock
N, Owen MJ, O’Donovan MC. 2011. Fine mapping of ZNF804A and
genome-wide significant evidence for its involvement in schizophrenia
and bipolar disorder. Mol Psychiatry 16:429–441.
Yan H, Yuan W, Velculescu VE, Vogelstein B, Kinzler KW. 2002. Allelic
variation in human gene expression. Science 297:1143.
SUPPORTING INFORMATION
Additional supporting information may be found in the online
version of this article at the publisher’s web-site.
